Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Interest Expense
Cost of servicing the company's debt during the period.
Exagen Inc.NASDAQ: XGN
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense growth accelerates
Q1 FY2026 interest expense of $1.27M rose 132.5% year over year, ahead of the +126.0% change in trailing-twelve-month interest expense. Sequentially, it fell 4.7% from the prior quarter. Over 3 fiscal years it compounded at +20.8% a year.
Context
- Interest expense amounted to 6.5% of revenue in FY2025, up 2.5 pp from a year earlier.
- Interest expense increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +132.5% holds above the trailing-twelve-month pace of +126.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 4.32M USD
- Year-over-year change
- +93.3%
- 4-year CAGR
- +13.3%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.32M | +93.3% |
| FY2024 | 2024-12-31 | 2.23M | -4.3% |
| FY2023 | 2023-12-31 | 2.34M | -4.6% |
| FY2022 | 2022-12-31 | 2.45M | -6.7% |
| FY2021 | 2021-12-31 | 2.63M | — |
Interest Expense vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's LTM Mar 2026 interest expense of $5.04M is the 4th highest of the 11 companies compared; the peer median is $1.68M.
- Its year-over-year change of +126.0% is the highest of 7, against a peer median of -15.1%.
- Interest expense amounts to 7.4% of revenue for XGN, versus a peer median of 2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.88M | — | +12.0% | 16.9% | |
| FY2025 | $12.16M | +59.4% | +64.3% | 11.3% | |
| LTM Mar 2026 | $7.24M | +73.3% | +187.4% | 6.7% | |
| LTM Mar 2026 | $5.04M | +126.0% | +20.8% | 7.4% | |
| LTM Mar 2026 | $2.61M | -44.7% | +4.8% | 3.3% | |
| LTM Jun 2026 | $2.58M | -55.6% | -20.9% | 0.3% | |
| LTM Mar 2026 | $785K | +14.4% | — | 1.9% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $481K | -65.8% | +42.5% | 4.7% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding XGN) | $1.68M | -15.1% | +27.2% | 2.6% | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.3M | 45.56M | 52.55M | 55.64M | 66.58M |
| Cost of Revenue | 20.59M | 24.21M | 23.09M | 22.53M | 27.78M |
| Gross Profit | 27.71M | 21.35M | 29.46M | 33.11M | 38.8M |
| Gross Margin | 57.4% | 46.9% | 56.1% | 59.5% | 58.3% |
| Research & Development | 7.24M | 9.88M | 4.87M | 5.38M | 6.25M |
| Selling, General & Admin | 44.54M | 52.02M | 47.43M | 41.37M | 46.62M |
| Operating Expenses | 51.78M | 67.4M | 52.29M | 46.75M | 52.87M |
| Depreciation & Amortization | 948K | 1.56M | 2.17M | 1.72M | 2.12M |
| EBITDA | (23.1M) | (43.66M) | (19.15M) | (11.15M) | (13.46M) |
| EBITDA Margin | -47.8% | -95.8% | -36.4% | -20.0% | -20.2% |
| Operating Income | (24.07M) | (46.05M) | (22.84M) | (13.64M) | (14.07M) |
| Operating Margin | -49.8% | -101.1% | -43.5% | -24.5% | -21.1% |
| Interest Income | 16K | 830K | 1.52M | 767K | 289K |
| Interest Expense | 2.63M | 2.45M | 2.34M | 2.23M | 4.32M |
| Other Income / Expenses | (2.61M) | (1.62M) | (819K) | (1.47M) | (5.83M) |
| Income Before Tax | (26.68M) | (47.67M) | (23.66M) | (15.1M) | (19.9M) |
| Pre-Tax Margin | -55.2% | -104.6% | -45.0% | -27.1% | -29.9% |
| Income Tax Expense | 175K | (282K) | 33K | 12K | 51K |
| Net Income | (26.85M) | (47.39M) | (23.69M) | (15.12M) | (19.95M) |
| Net Margin | -55.6% | -104.0% | -45.1% | -27.2% | -30.0% |
| EPS (Basic) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| EPS (Diluted) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| Weighted Avg Shares | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
| Weighted Avg Shares (Diluted) | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.